William Hutto, OD
Optometrist · High Point, NCNPI 1821191669
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.5%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Coopervision Inc. at 37.8% of the total. 2025 is the largest year on record at $13,376, more than ten times the $852 reported in 2019. Among optometrist clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 264 payments — averaging $76.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coopervision Inc.$8K
- Alcon$7K
- Johnson & Johnson Vision Care, Inc.$3K
- Bausch & Lomb Americas Inc.$1K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$464
- Sun Pharmaceutical Industries Inc.$339
- plus $857 from 13 others
What the payments were for
- Consulting fees$1,7309%
- Speaking & faculty fees$11,36057%
- Food & beverage$7,00335%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coopervision Inc. | 77 | $7,592 |
| Alcon | 55 | $7,032 |
| Johnson & Johnson Vision Care, Inc. | 36 | $2,526 |
| Bausch & Lomb Americas Inc. | 36 | $1,282 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 18 | $464 |
| Sun Pharmaceutical Industries Inc. | 17 | $339 |
| Tarsus Pharmaceuticals, Inc. | 4 | $224 |
| Biotissue Holdings Inc. | 2 | $126 |
| Kala Pharmaceuticals, Inc. | 2 | $112 |
| Aerie Pharmaceuticals, Inc. | 1 | $64 |
| AbbVie | 3 | $62 |
| Oyster Point Pharma, Inc. | 2 | $56 |
| Harrow Eye, LLC | 2 | $55 |
| Novartis | 2 | $41 |
| Shire North American Group Inc | 2 | $36 |
| Optos, Inc. | 2 | $26 |
| Dompe US, Inc. | 1 | $24 |
| Sight Sciences, Inc. | 1 | $16 |
| Topcon Healthcare, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CVI Contact Lens$6,000
- Precision 1$5,360
- Precision7$5,211
- DAILIES TOTAL1$5,110
- TOTAL30$5,110
- Acuvue$1,730
- INFUSE$358
- Clareon$287
- MiSight Contact Lens$229
- Wavelight Sightmap$150
- XDEMVY$122
- INFUSE MULTIFOCAL$116
- MyDay Contact Lens$103
- TRYPTYR$100
How this compares
$20,093 in reported general payments places this provider in the 95th percentile of 1,326 optometrist providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 31 | $36,215 |
| Fluorometholone | 25 | $2,341 |
| Travoprost | 11 | $2,169 |
| Latanoprost | 122 | $1,484 |
| Brimonidine Tartrate | 17 | $1,111 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 33 | $555 |
| Dorzolamide Hcl | 14 | $555 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 34 | $366 |
| Doxycycline Hyclate | 13 | $353 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 26 | $229 |
| Timolol Maleate | 31 | $194 |
| Cephalexin | 13 | $95 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $62 | $36,21531 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,326 optometrist providers in North Carolina.
Other optometrist in High Point
- Crystal BrimerWilmington$920K
- Osama SaidRaleigh$597K
- Ryan CorteAsheville$569K
- Sanjay PatelApex$518K
- Sean SmolenyakRaleigh$512K
- Rachael WrubleBelmont$228K
- Lisa GreeneArden$186K
- Jennifer LyerlyMorrisville$164K
- Timothy PoirierKnightdale$130K
- Randall ThomasConcord$126K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.